Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Lymphoma, B-Cell Clinical Trials

A listing of Lymphoma, B-Cell medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (571) clinical trials

People with chronic lymphocytic leukemia are asked to participate in a research study being conducted by White Plains Hospital.

Phase N/A

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Background The treatment of the intermediate and aggressive non-Hodgkin's lymphomas in adults and children commonly induces complete responses in a sizable fraction of the treated population, and about 2/3 of the complete responders appear to have prolonged disease-free survival. The present study assesses the activity and tolerability in previously untreated ...

Phase

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

Background The evaluation of the cells of the immune system and HTLV-1 infection have been a central focus of the Metabolism Branch for the past 30 years. Blood obtained by apheresis or blood drawing, skin biopsies and other tissues will be evaluated for abnormalities related to immunity, HTLV-1 infection and ...

Phase N/A

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Background This is a study to investigate in a preliminary fashion the feasibility of short course chemotherapy to patients with HIV-associated non-Hodgkin's lymphoma (HIV-NHL). This study will investigate if the paradigm for treatment can be successfully changed from a standard of 6 cycles to one cycle beyond complete remission with ...

Phase

Clinical Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Background Persons may be prone to develop hematologic or lymphoproliferative cancer for a variety of reasons including: inherited predisposition of benign, premalignant, or malignant conditions; environmental exposures shared by family members; previous tumors or preneoplastic conditions; immune deficiency; or, stochastic processes Investigations of individuals and families at high risk of ...

Phase N/A

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 (durvalumab) as monotherapy or in combination with either tremelimumab or AZD9150. The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or ...

Phase

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

PRIMARY OBJECTIVES: I. To determine if vitamin D replacement in vitamin D insufficient patients with newly diagnosed untreated diffuse large B-cell lymphoma (DLBCL) can improve event free survival at 12 months to be equivalent to that of a control population of vitamin D sufficient patients. (Study I) II. To assess ...

Phase N/A

Lenalidomide MTX Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas

Phase I The goal of the phase I part of the study is to determine the maximum tolerated doses of methotrexate and cytarabine able to be combined with once-per-cycle rituximab and full-dose 3-weeks-on/1-week-off lenalidomide in 28-day treatment cycles. Methotrexate and cytarabine will be given three times per cycle, preferably on ...

Phase

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Part 1 will follow a rolling six dose escalation schedule of AZD3965 until a tolerated dose at which MCT1 is inhibited (as measured by at least a four-fold change relative to baseline in peak lactate levels in PBMCs) and/or the maximum tolerated dose (MTD) is defined. Approximately 36 patients with ...

Phase

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS collects contact, sociodemographic and health information about participants. This information is entered into CoRDS and linked to a unique coded identifier. Below are some examples of information requested on the Questionnaire that will be entered into CoRDS: Contact information: Name, Mailing Address, Phone Number, Email Address Sociodemographic information: Date ...

Phase N/A